Although this study was not designed to assess clinical outcome, its results raise the possibility that despite the failure of tocilizumab in a recent clinical trial to slow the rate of C-peptide decline in new onset diabetes, other IL-6–targeted therapies may be effective in T1D. This evidence concerns the gene IL6 and type 1 diabetes mellitus.